Damora Therapeutics, Inc. - Common Stock (DMRA) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently weak earnings tone.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
53/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$30.95
Trend Context
Mixed / range
Latest briefing
What's happening with DMRA
globenewswire.com1 Jul 2026
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com27 May 2026
Damora Therapeutics: Well-Funded Moonshot For CALR Mutations
Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They have approximately $562.3 million in cash, and management believes this gives them enough runway into 2029. DMRA's lead asset has potential competitors in more advanced R&D stages. This helps validate the asset class as a whole, but DMRA still needs more data of its own.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com12 May 2026
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit first regulatory submissions to enable clinical development for DMR-001, an Fc-null anti-mutCALR antibody, and DMR-002, an Fc-enhanced anti-mutCALR antibody, in mid-2026 and second-half 2026, respectively – – Appointed CEO and key leadership team members to accelerate vision of redefining care for patients with mutCALR-dr…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
defenseworld.net
23 Apr 2026
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Recommendation of “Moderate Buy” by Analysts
